Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines

Omadacycline (Nuzyra®) is a new aminomethylcycline, approved by the U. S. Food and Drug Administration in 2018, as a tetracycline antibacterial. It can be used in community-acquired pneumonia and in acute bacterial skin and skin-structure infections. It was developed and is commercialized by Paratek...

Full description

Saved in:
Bibliographic Details
Published inPharmaceuticals (Basel, Switzerland) Vol. 12; no. 2; p. 63
Main Authors Durães, Fernando, Sousa, Emília
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 21.04.2019
MDPI
Subjects
aminomethylcycline
antibacterial
Antimicrobial agents
Bacteria
Binding sites
Brief Report
Drugs
FDA approval
FDA approved
Gram-positive bacteria
Mutation
Omadacycline
Pharmaceuticals
protein synthesis inhibitor
Streptococcus infections
tetracycline
antibacterial
tetracycline
aminomethylcycline
Omadacycline
protein synthesis inhibitor
FDA approved
Online AccessGet full text

Cover

More Information
Summary:Omadacycline (Nuzyra®) is a new aminomethylcycline, approved by the U. S. Food and Drug Administration in 2018, as a tetracycline antibacterial. It can be used in community-acquired pneumonia and in acute bacterial skin and skin-structure infections. It was developed and is commercialized by Paratek Pharmaceuticals. It is a semisynthetic compound, derived from minocycline, capable of evading widely distributed efflux and target protection antibacterial resistance mechanisms and has demonstrated activity in a broad spectrum of bacteria.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1424-8247
1424-8247
DOI:10.3390/ph12020063